Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Gain Therapeutics ( (GANX) ) is now available.
On December 18, 2025, Gain Therapeutics reported exploratory endpoint data from Part 1 of its Phase 1b clinical study of GT-02287 in people with Parkinson’s disease, showing that all participants with elevated cerebrospinal fluid glucosylsphingosine experienced large reductions toward levels seen in healthy individuals after 90 days of treatment. The 21-patient study saw 19 complete the three‑month dosing period and 15 opt into a nine‑month extension that is expected to conclude in September 2026, with GT‑02287 remaining generally well tolerated at projected therapeutic exposures and the data monitoring committee recommending continuation without changes; combined with Phase 1 data in healthy volunteers demonstrating favorable safety, central nervous system exposure and target engagement, and confirmation that its current capital should fund operations through the Phase 1b extension and year‑end 2026, the company has strengthened its clinical and financial footing in the competitive Parkinson’s drug development space.
The most recent analyst rating on (GANX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Gain Therapeutics stock, see the GANX Stock Forecast page.
Spark’s Take on GANX Stock
According to Spark, TipRanks’ AI Analyst, GANX is a Neutral.
Gain Therapeutics is currently challenged by significant financial difficulties, with no revenue growth and persistent losses impacting profitability. These weaknesses heavily weigh down the stock score. Despite these challenges, technical analysis shows mixed signals, and recent positive corporate events related to Parkinson’s treatment offer some hope for future prospects. However, the negative valuation metrics further underscore the risks, leading to an overall cautious outlook.
To see Spark’s full report on GANX stock, click here.
More about Gain Therapeutics
Gain Therapeutics is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases, with a current focus on Parkinson’s disease. Its lead candidate, GT-02287, targets glucocerebrosidase (GCase) pathways and is being evaluated for use in patients with Parkinson’s disease both with and without GBA1 mutations, reflecting a strategy aimed at disease-modifying treatment in a large neurodegenerative market.
Average Trading Volume: 1,081,041
Technical Sentiment Signal: Buy
Current Market Cap: $148.5M
See more data about GANX stock on TipRanks’ Stock Analysis page.